Published online May 28, 2021. doi: 10.3748/wjg.v27.i20.2643
Peer-review started: February 6, 2021
First decision: February 27, 2021
Revised: March 13, 2021
Accepted: April 23, 2021
Article in press: April 23, 2021
Published online: May 28, 2021
Processing time: 102 Days and 9.6 Hours
Pancreatic cancer is the seventh most common cause of death among malignant tumors in women. It represents one of the deadliest types of cancer with overall 5-year survival rate < 10%.
Although the understanding of the etiology of pancreatic cancer has improved over the past decades and certain risk factors have been established, the causes of pancreatic cancer are still insufficiently known. Results of epidemiological studies show conflicting results regarding the association of the use of oral contraceptives (OC) and risk for pancreatic cancer.
The aim of this study was to evaluate the relationship between the use of OC and risk for pancreatic cancer.
A comprehensive literature search was performed based on defined inclusion and exclusion criteria. Quality of included observational studies was assessed and data was extracted. A meta-analysis of ever-use vs never-use of OC and risk for pancreatic cancer was performed using Review Manager 5.3. In addition, the association between the duration of use of OC and pancreatic cancer risk was also assessed, and a subgroup analysis was performed.
A total of 7700 cases of pancreatic cancer from 21 studies (10 case-control and 11 cohort) were included in this meta-analysis. A significant association was observed between the ever-use of OC and pancreatic cancer risk (relative risk = 0.85; 95% confidence interval: 0.73-0.98), while the duration of use (< 1 year, < 5 years, 5-10 years, > 10 years) did not show a significant association. Subgroup analysis revealed a statistically significant decrease in pancreatic cancer and use of OC in high quality studies, studies conducted in Europe and in postmenopausal women.
This meta-analysis suggests a protective effect of the use of OC and pancreatic cancer occurrence, however more epidemiological studies are necessary to fully elucidate this association.
Further epidemiological studies are warranted to fully assess the association between the use of OC and risk for pancreatic cancer. These future studies investigating the risk for pancreatic cancer should be well-designed and include detailed questions regarding the use of OC.